Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | Director · Chief Executive Officer | April 07, 2026 | April 09, 2026 |
| LadRx CorpLADX · Entity 94858 | Director | January 15, 2024 | January 29, 2024 |
| NeuroSense Therapeutics Ltd.NRSN · Entity 7767 | Director | March 18, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,417 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 37,985 · Balance 40,417 F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.
LadRx Corp
Report date January 15, 2024 · Filed January 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.83 · Expires 2034-01-14 | Direct | 5,000 |
Reported balance
After 2024-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-15 · Grant · Acquired 5,000 · Balance 5,000 F1: The stock options vested 50% on the date of grant and the remainder vests in substantially equal installments each month for a period of three (3) years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vested 50% on the date of grant and the remainder vests in substantially equal installments each month for a period of three (3) years from the date of grant.
NeuroSense Therapeutics Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 48,000 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 48,000 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 60,000 F1: These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 99,898 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 99,898 F2: These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. |
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2032-03-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: These options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F2: These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F3: These options are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 9, 2026 21:00 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 37,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-042050 · ownership.xml · nonDerivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,417 F1 · shares: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:01 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 138,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001213900-25-050017 · ownership.xml · derivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,000 Underlying: Common Stock · 138,000 shares Expires 2035-05-28 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. Read SEC document |
| December 05, 2024 Filed Dec 5, 2024 22:47 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001213900-24-106119 · ownership.xml · derivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-12-04 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing December 5, 2024. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing December 5, 2024. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 22:06 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001213900-24-026712 · ownership.xml · derivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-24 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024. Read SEC document |
| January 15, 2024 Filed Jan 29, 2024 16:06 UTC | LadRx Corp LADX · Entity 94858 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001493152-24-004138 · ownership.xml · derivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-01-14 F1 · derivative.exercise_date: The stock options vested 50% on the date of grant and the remainder vests in substantially equal installments each month for a period of three (3) years from the date of grant. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:36 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001213900-23-043111 · ownership.xml · derivative · entry 2 Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-05-23 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:36 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 420,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-043111 · ownership.xml · nonDerivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,520,000 Read SEC document |
| September 20, 2022 Filed Sep 20, 2022 23:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 75,000 | $0.42 | $31,515.00 |
DisclosureSEC source: 0001213900-22-057513 · ownership.xml · nonDerivative · entry 2 Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,000 F2 · price: The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4079 through $0.4230, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 23:11 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 25,000 | $0.43 | $10,735.00 |
DisclosureSEC source: 0001213900-22-057513 · ownership.xml · nonDerivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,000 F1 · price: The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4196 through $0.4573, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 20:42 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-050082 · ownership.xml · nonDerivative · entry 1 Claiborne Cary J · CIK 0001370930 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 F1 · shares: These are Restricted Stock Units that vest monthly pro rata over the next 36 months. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 19:54 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantEmployee Stock Option · Derivative | 6,667 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-22-009419 · ownership.xml · derivative · entry 1 Claiborne Cary J · CIK 0001370930 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2032-02-22 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 02:23 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock options · Derivative | 130,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001213900-21-064281 · ownership.xml · derivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common stock · 130,000 shares Expires 2031-12-08 F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:35 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001213900-21-056466 · ownership.xml · derivative · entry 1 Claiborne Cary J · CIK 0001370930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-11-01 F1 · shares: The option vests pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.